Sign In
14 Feb 2019 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx announces directorate update and grant of options
Alderley Park, 14 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that further to the announcement made on 19 November 2018, James Mead assumed his new role as Chief Financial Officer on 1 February 2019 and has become a member of Redx Pharma's Board of Directors.
In addition, the company announces that on 13 February 2019, options over 1,200,000 ordinary shares of 1p each in the share capital of the Company, were granted to James Mead, Chief Financial Officer, on the following basis:
Granted 1,200,000 Options under Redx's Enterprise Management Incentive Scheme.
200,000 options are exercisable at a price of 13.75p and will vest immediately200,000 options are exercisable at a price of 20p and will vest immediately200,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant,
200,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant,200,000 options are exercisable at a price of 42.5p and will vest on the 2-year anniversary of the grant.200,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.
None of these options will become exercisable until the second anniversary of grant.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 920 |
Lisa Anson, Chief Executive Officer |
|
|
|
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a. | Name | James Mead |
2 | Reason for notification |
|
a. | Position/Status | Chief Financial Officer |
b. | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a. | Name | Redx Pharma Plc |
b. | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a. | Description of the financial instrument, type of instrument Identification Code | Options over Ordinary Shares of 1p each
ISIN: GB00BSNB6S51 |
b. | Nature of the transaction | Grant of options under the EMI Share Scheme
|
c. | Price(s) and volume(s) | Granted 1,200,000 Options under Redx's Enterprise Management Incentive Scheme.
200,000 options are exercisable at a price of 13.75p and will vest immediately 200,000 options are exercisable at a price of 20p and will vest immediately 200,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant,
200,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant, 200,000 options are exercisable at a price of 42.5p and will vest on the 2-year anniversary of the grant. 200,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.
|
d. | Aggregated information - Aggregated Volume - Price | N/A - Single Transaction |
e. | Date of the transaction | 13/02/2019 |
f. | Place of the transaction | Outside of trading venue |
Follow the stocks
